doi: 10.1016/j.immuni.2015.05.018 69 DeRubertisBGStilesBMBhargavaAGusaniNJHezelMDAngelicaMet al
2025;6:1001378 DOI: Received: October 01, 2025 Accepted: December 04, 2025 Published: December 17, 2025 Academic Editor: Alessandro Granito, University of Bologna, Italy The management of metabolic dysfunction-associated steatohepatitis (MASH) has evolved significantly, transitioning from a lack of therapeutic options to resmetiroma and semaglutide being licensed for use in MASH
More than 2500 diabetes-free individuals with weight-related complications were recruited for the study who were further divided into groups
314 ISRIB restores eIF2B function and enhances gemcitabine-induced pancreatic cancer cell death
The increase raises Gilead's plans to $32 billion out to 2030, a programme that overall includes three new facilities, alongside upgrades to three existing sites to expand the company's US manufacturing and R&D capabilities